YposKesi, developer of gene and cell therapy products for rare diseases, has appointed Alain Lamproye as its CEO. Lamproye, an expert in industrial bioproduction, most recently served as Chairman of the BioPharma Business Unit of Novasep’s Belgian gene therapy subsidiary.
Galapagos: To the clinic
AppointmentsMechelen-based biotech Galapagos NV has appointed Walid Abi-Saab to the role of Chief Medical Officer.
Pharmalink: Global chair
AppointmentsSpecialty pharma company Pharmalink AB has elected Maria Carell as Chair of the Board of Directors. Carell replaces Hilde Furberg, who will take over as Vice Chair.
Oryzon Genomics: Alzheimer aid
AppointmentsBarcelona-based epigenetics specialist Oryzon Genomics has made new additions to its Scientific Advisory Board in order to be prepared for the completion of its Phase I trial for dementia drug ORY-2001. Renowned Alzheimer’s disease expert Howard Fillit will take over a seat on the board.
Bavarian Nordic: Head of strategy
AppointmentsGoing forward, Henrik Birk will be in charge of Bavarian Nordic’s operational and HR strategies. He will take over the newly created position of Chief Operating Officer at the Danish-German biotech.
YposKesi: Bioproduction specialist
AppointmentsYposKesi, developer of gene and cell therapy products for rare diseases, has appointed Alain Lamproye as its CEO. Lamproye, an expert in industrial bioproduction, most recently served as Chairman of the BioPharma Business Unit of Novasep’s Belgian gene therapy subsidiary.
Nestle researchers link IBS to anxiety
Latest NewsResearchers at Nestlé Research Center in Lausanne and Canadian collaborators have found that the microbiome of irritable bowel syndrome patients affects their susceptibility for anxiety disorders.
BenevolentBio: Robot work
AppointmentsSartorius: On top of finances
AppointmentsGerman lab equipment provider Sartorius has appointed Rainer Lehmann to the Executive Board. Lehmann will be overseeing the Finance, Human Resources Management and Information Technology functions.
FDA grants Priority Review to avelumab
Latest NewsAvelumab, Merck KGaA’s and Pfizer’s Phase III checkpoint inhibitor, has been granted Priority Review from the US Food and Drug Administration in urothelial carcinoma patients who progressed on or after platinum-based chemotherapy.
Big Pharma pushing up orphan drug prices
Latest NewsThe times in which biotechs dominate the orphan drug market are over. A report from business intelligence provider Evaluate Ltd. concludes that only three in ten OD developers are still biotech SMEs.